EP3703661A1 - Compositions de matrices solides à point de congélation abaissé pour la granulation à l'état fondu d'enzymes - Google Patents
Compositions de matrices solides à point de congélation abaissé pour la granulation à l'état fondu d'enzymesInfo
- Publication number
- EP3703661A1 EP3703661A1 EP18804821.9A EP18804821A EP3703661A1 EP 3703661 A1 EP3703661 A1 EP 3703661A1 EP 18804821 A EP18804821 A EP 18804821A EP 3703661 A1 EP3703661 A1 EP 3703661A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fpdsm
- enzyme
- urea
- solid
- betaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 301
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 301
- 239000000203 mixture Substances 0.000 title claims abstract description 281
- 239000007787 solid Substances 0.000 title claims abstract description 197
- 239000011159 matrix material Substances 0.000 title claims abstract description 22
- 230000000994 depressogenic effect Effects 0.000 title claims abstract description 15
- 230000008014 freezing Effects 0.000 title claims abstract description 15
- 238000007710 freezing Methods 0.000 title claims abstract description 15
- 238000007909 melt granulation Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 132
- 238000009472 formulation Methods 0.000 claims abstract description 80
- 230000015556 catabolic process Effects 0.000 claims abstract description 14
- 238000006731 degradation reaction Methods 0.000 claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 351
- 229940088598 enzyme Drugs 0.000 claims description 297
- 239000004202 carbamide Substances 0.000 claims description 176
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 134
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 117
- 229960003237 betaine Drugs 0.000 claims description 82
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 74
- 235000019743 Choline chloride Nutrition 0.000 claims description 74
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 74
- 229960003178 choline chloride Drugs 0.000 claims description 74
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 72
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 61
- 239000008101 lactose Substances 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 59
- 230000002255 enzymatic effect Effects 0.000 claims description 58
- 102000035195 Peptidases Human genes 0.000 claims description 55
- 108091005804 Peptidases Proteins 0.000 claims description 55
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 54
- 239000008103 glucose Substances 0.000 claims description 54
- 238000003860 storage Methods 0.000 claims description 50
- 239000004365 Protease Substances 0.000 claims description 46
- -1 chymosins Proteins 0.000 claims description 44
- 239000007921 spray Substances 0.000 claims description 43
- 239000007788 liquid Substances 0.000 claims description 41
- 235000019270 ammonium chloride Nutrition 0.000 claims description 36
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 35
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 33
- 239000000600 sorbitol Substances 0.000 claims description 33
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 28
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 28
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 28
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 28
- 238000011084 recovery Methods 0.000 claims description 28
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 27
- 102000004316 Oxidoreductases Human genes 0.000 claims description 24
- 108090000854 Oxidoreductases Proteins 0.000 claims description 24
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 18
- 102000013142 Amylases Human genes 0.000 claims description 17
- 108010065511 Amylases Proteins 0.000 claims description 17
- 229930091371 Fructose Natural products 0.000 claims description 17
- 239000005715 Fructose Substances 0.000 claims description 17
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 17
- 102000004157 Hydrolases Human genes 0.000 claims description 16
- 108090000604 Hydrolases Proteins 0.000 claims description 16
- 108010059820 Polygalacturonase Proteins 0.000 claims description 15
- 235000019418 amylase Nutrition 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 108010084185 Cellulases Proteins 0.000 claims description 14
- 102000005575 Cellulases Human genes 0.000 claims description 14
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 14
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 14
- 229960003403 betaine hydrochloride Drugs 0.000 claims description 14
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 claims description 14
- 108010018734 hexose oxidase Proteins 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 239000011975 tartaric acid Substances 0.000 claims description 14
- 235000002906 tartaric acid Nutrition 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 229920001503 Glucan Polymers 0.000 claims description 12
- 108090001060 Lipase Proteins 0.000 claims description 11
- 229940023579 anhydrous betaine Drugs 0.000 claims description 11
- 102000004882 Lipase Human genes 0.000 claims description 10
- 239000004367 Lipase Substances 0.000 claims description 10
- 102000004357 Transferases Human genes 0.000 claims description 10
- 108090000992 Transferases Proteins 0.000 claims description 10
- 235000019421 lipase Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 230000000087 stabilizing effect Effects 0.000 claims description 10
- 108010013043 Acetylesterase Proteins 0.000 claims description 9
- 108090000371 Esterases Proteins 0.000 claims description 9
- 102000004195 Isomerases Human genes 0.000 claims description 9
- 108090000769 Isomerases Proteins 0.000 claims description 9
- 108010029541 Laccase Proteins 0.000 claims description 9
- 102000004317 Lyases Human genes 0.000 claims description 9
- 108090000856 Lyases Proteins 0.000 claims description 9
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 claims description 9
- 108010005400 cutinase Proteins 0.000 claims description 9
- 235000011073 invertase Nutrition 0.000 claims description 9
- 108090000915 Aminopeptidases Proteins 0.000 claims description 8
- 102000004400 Aminopeptidases Human genes 0.000 claims description 8
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 8
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 8
- 102000012286 Chitinases Human genes 0.000 claims description 8
- 108010022172 Chitinases Proteins 0.000 claims description 8
- 102100022624 Glucoamylase Human genes 0.000 claims description 8
- 108010015776 Glucose oxidase Proteins 0.000 claims description 8
- 108090000364 Ligases Proteins 0.000 claims description 8
- 102000003960 Ligases Human genes 0.000 claims description 8
- 102000003992 Peroxidases Human genes 0.000 claims description 8
- 108060008539 Transglutaminase Proteins 0.000 claims description 8
- 102000003425 Tyrosinase Human genes 0.000 claims description 8
- 108060008724 Tyrosinase Proteins 0.000 claims description 8
- 229960001040 ammonium chloride Drugs 0.000 claims description 8
- 229940025131 amylases Drugs 0.000 claims description 8
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 8
- 235000019420 glucose oxidase Nutrition 0.000 claims description 8
- 235000019833 protease Nutrition 0.000 claims description 8
- 102000003601 transglutaminase Human genes 0.000 claims description 8
- 108010011619 6-Phytase Proteins 0.000 claims description 7
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 7
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 7
- 108010053835 Catalase Proteins 0.000 claims description 7
- 102000016938 Catalase Human genes 0.000 claims description 7
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 7
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 7
- 101001096557 Dickeya dadantii (strain 3937) Rhamnogalacturonate lyase Proteins 0.000 claims description 7
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 7
- 108050008938 Glucoamylases Proteins 0.000 claims description 7
- 108010060309 Glucuronidase Proteins 0.000 claims description 7
- 102000053187 Glucuronidase Human genes 0.000 claims description 7
- 108010054377 Mannosidases Proteins 0.000 claims description 7
- 102000001696 Mannosidases Human genes 0.000 claims description 7
- 108700020962 Peroxidase Proteins 0.000 claims description 7
- 108090001066 Racemases and epimerases Proteins 0.000 claims description 7
- 102000004879 Racemases and epimerases Human genes 0.000 claims description 7
- 108010083644 Ribonucleases Proteins 0.000 claims description 7
- 102000006382 Ribonucleases Human genes 0.000 claims description 7
- 108010009043 arylesterase Proteins 0.000 claims description 7
- 102000028848 arylesterase Human genes 0.000 claims description 7
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 229960004106 citric acid Drugs 0.000 claims description 7
- 229940119679 deoxyribonucleases Drugs 0.000 claims description 7
- 108010002430 hemicellulase Proteins 0.000 claims description 7
- 108010087558 pectate lyase Proteins 0.000 claims description 7
- 108010072638 pectinacetylesterase Proteins 0.000 claims description 7
- 102000004251 pectinacetylesterase Human genes 0.000 claims description 7
- 108020004410 pectinesterase Proteins 0.000 claims description 7
- 230000002351 pectolytic effect Effects 0.000 claims description 7
- 229920005862 polyol Polymers 0.000 claims description 7
- 125000003147 glycosyl group Chemical group 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 108010059892 Cellulase Proteins 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 description 152
- 235000018102 proteins Nutrition 0.000 description 149
- 102000004169 proteins and genes Human genes 0.000 description 149
- 239000002904 solvent Substances 0.000 description 63
- 235000019419 proteases Nutrition 0.000 description 36
- 230000008018 melting Effects 0.000 description 28
- 238000002844 melting Methods 0.000 description 28
- 238000007792 addition Methods 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 108090000787 Subtilisin Proteins 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- LKDMKWNDBAVNQZ-WJNSRDFLSA-N 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-WJNSRDFLSA-N 0.000 description 13
- 239000004382 Amylase Substances 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000007711 solidification Methods 0.000 description 12
- 230000008023 solidification Effects 0.000 description 12
- 108010082371 succinyl-alanyl-alanyl-prolyl-phenylalanine-4-nitroanilide Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 230000017854 proteolysis Effects 0.000 description 9
- 230000002779 inactivation Effects 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000011877 solvent mixture Substances 0.000 description 7
- 238000009987 spinning Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 108010056079 Subtilisins Proteins 0.000 description 4
- 102000005158 Subtilisins Human genes 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- UOIZISQJANIWCZ-UHFFFAOYSA-N azane;urea;hydrochloride Chemical compound [NH4+].[Cl-].NC(N)=O UOIZISQJANIWCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000005496 eutectics Effects 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003262 industrial enzyme Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 3
- 108010024976 Asparaginase Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 108010093305 exopolygalacturonase Proteins 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 2
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 2
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 2
- 108010080981 3-phytase Proteins 0.000 description 2
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 description 2
- 102000006267 AMP Deaminase Human genes 0.000 description 2
- 108700016228 AMP deaminases Proteins 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100040894 Amylo-alpha-1,6-glucosidase Human genes 0.000 description 2
- 108010033764 Amylosucrase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102100032487 Beta-mannosidase Human genes 0.000 description 2
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 2
- 108090001069 Chymopapain Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 2
- 102100035149 Cytosolic endo-beta-N-acetylglucosaminidase Human genes 0.000 description 2
- 108030002106 D-psicose 3-epimerases Proteins 0.000 description 2
- 108030001574 Deuterolysin Proteins 0.000 description 2
- 108010012023 Dextrin dextranase Proteins 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000270 Ficain Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 102000055441 Gastricsin Human genes 0.000 description 2
- 108090001072 Gastricsin Proteins 0.000 description 2
- 108010022769 Glucan 1,3-beta-Glucosidase Proteins 0.000 description 2
- 108010073324 Glutaminase Proteins 0.000 description 2
- 102000009127 Glutaminase Human genes 0.000 description 2
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 2
- 102100036269 Hexosaminidase D Human genes 0.000 description 2
- 108010042889 Inulosucrase Proteins 0.000 description 2
- 108010028688 Isoamylase Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 102100033468 Lysozyme C Human genes 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 108030004673 Mannuronate-specific alginate lyases Proteins 0.000 description 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 2
- 102100030397 N-acetylmuramoyl-L-alanine amidase Human genes 0.000 description 2
- 102000048245 N-acetylneuraminate lyases Human genes 0.000 description 2
- 108700023220 N-acetylneuraminate lyases Proteins 0.000 description 2
- 108060004757 N-acyl-D-amino-acid deacylase Proteins 0.000 description 2
- 108030006755 N-acyl-aliphatic-L-amino acid amidohydrolases Proteins 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- 108010033272 Nitrilase Proteins 0.000 description 2
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108030006205 Pectate trisaccharide-lyases Proteins 0.000 description 2
- 108010029182 Pectin lyase Proteins 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000313 Pepsin B Proteins 0.000 description 2
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 2
- 108030006253 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidases Proteins 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 108090000553 Phospholipase D Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 2
- 108090000919 Pyroglutamyl-Peptidase I Proteins 0.000 description 2
- 102100031108 Pyroglutamyl-peptidase 1 Human genes 0.000 description 2
- 108030006203 Rhamnogalacturonan endolyases Proteins 0.000 description 2
- 108090000899 Serralysin Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108030003984 Thiol oxidases Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 2
- 229920002000 Xyloglucan Polymers 0.000 description 2
- 102100029089 Xylulose kinase Human genes 0.000 description 2
- 108091022925 [glutamine synthetase]-adenylyl-L-tyrosine phosphorylase Proteins 0.000 description 2
- 108010093941 acetylxylan esterase Proteins 0.000 description 2
- 108090000350 actinidain Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 108091022872 aldose 1-epimerase Proteins 0.000 description 2
- 102000020006 aldose 1-epimerase Human genes 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
- 108010044879 alpha-L-rhamnosidase Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010019077 beta-Amylase Proteins 0.000 description 2
- 108010055059 beta-Mannosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010048610 cellobiose phosphorylase Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 108010042194 dextransucrase Proteins 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 108090000285 fruit bromelain Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000013038 hand mixing Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 108090000021 oryzin Proteins 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000006432 protein unfolding Effects 0.000 description 2
- 108010001816 pyranose oxidase Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108010035322 rhamnogalacturonan acetylesterase Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 108090000346 stem bromelain Proteins 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 108090000135 streptogrisin A Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 108010038851 tannase Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108020005087 unfolded proteins Proteins 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 108091022915 xylulokinase Proteins 0.000 description 2
- KDXKERNSBIXSRK-RGXOIRHWSA-N (2s)-6-amino-2-(deuterioamino)hexanoic acid Chemical compound [2H]N[C@H](C(O)=O)CCCCN KDXKERNSBIXSRK-RGXOIRHWSA-N 0.000 description 1
- YPUDISCJWPUYAX-VRPWFDPXSA-N (3S,4S,5R)-2-amino-2,5-bis(hydroxymethyl)oxolane-3,4-diol Chemical compound OCC1(N)O[C@H](CO)[C@@H](O)[C@@H]1O YPUDISCJWPUYAX-VRPWFDPXSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100030492 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- CHUGKEQJSLOLHL-UHFFFAOYSA-N 2,2-Bis(bromomethyl)propane-1,3-diol Chemical compound OCC(CO)(CBr)CBr CHUGKEQJSLOLHL-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 102100036426 Acid phosphatase type 7 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102100025677 Alkaline phosphatase, germ cell type Human genes 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 101710199313 Alpha-L-arabinofuranosidase Proteins 0.000 description 1
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102100025981 Aminoacylase-1 Human genes 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 102100023943 Arylsulfatase L Human genes 0.000 description 1
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 101000709143 Aspergillus aculeatus Rhamnogalacturonate lyase A Proteins 0.000 description 1
- 101001065065 Aspergillus awamori Feruloyl esterase A Proteins 0.000 description 1
- 108010043037 Aspergillus exonuclease Proteins 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 101710204694 Beta-xylosidase Proteins 0.000 description 1
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010035722 Chloride peroxidase Proteins 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 102100039501 Chymotrypsinogen B Human genes 0.000 description 1
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
- 102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 108700036010 EC 3.4.21.65 Proteins 0.000 description 1
- 108700033915 EC 3.4.23.22 Proteins 0.000 description 1
- 108700033917 EC 3.4.23.23 Proteins 0.000 description 1
- 108010092208 Endothia aspartic proteinase Proteins 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 102100039835 Galactoside alpha-(1,2)-fucosyltransferase 1 Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108030002455 Glutathione amide-dependent peroxidases Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010010525 Isomaltulose synthase Proteins 0.000 description 1
- 101710184220 Kappa-carrageenase Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108090000131 Metalloendopeptidases Proteins 0.000 description 1
- 102000003843 Metalloendopeptidases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000034452 Methionyl aminopeptidases Human genes 0.000 description 1
- 102100032519 Mitochondrial ribonuclease P catalytic subunit Human genes 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 1
- 101710203791 Mucorpepsin Proteins 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000728666 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Putative rhamnogalacturonase Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 1
- 108010073038 Penicillin Amidase Proteins 0.000 description 1
- 241001123663 Penicillium expansum Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108010044302 Phosphoinositide phospholipase C Proteins 0.000 description 1
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 102100032967 Phospholipase D1 Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 1
- 108030006244 Protein-glutamine glutaminases Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101710148480 Putative beta-xylosidase Proteins 0.000 description 1
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 description 1
- 101710193171 Pyranose dehydrogenase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108030000574 Serine-type carboxypeptidases Proteins 0.000 description 1
- 102000034328 Serine-type carboxypeptidases Human genes 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710181297 Thermomycolin Proteins 0.000 description 1
- 101710167005 Thiol:disulfide interchange protein DsbD Proteins 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 101710158370 Xylan 1,4-beta-xylosidase Proteins 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 1
- 108010061261 alpha-glucuronidase Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 108010052085 cellobiose-quinone oxidoreductase Proteins 0.000 description 1
- 108010080434 cephalosporin-C deacetylase Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108010089807 chitosanase Proteins 0.000 description 1
- 108010025790 chlorophyllase Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 108010027293 diisopropyl-fluorophosphatase Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 108010092086 exo-poly-alpha-galacturonosidase Proteins 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 108010075712 fatty acid reductase Proteins 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010058100 fructan beta-fructosidase Proteins 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010079306 galactoside 2-alpha-L-fucosyltransferase Proteins 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011090 industrial biotechnology method and process Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108010031620 mandelonitrile lyase Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000289 melt material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010009674 methylaspartate mutase Proteins 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940066716 pepsin a Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013308 plastic optical fiber Substances 0.000 description 1
- 239000013309 porous organic framework Substances 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010016615 rhamnogalacturonan rhamnohydrolase Proteins 0.000 description 1
- 108010029529 rhamnogalacturonase A Proteins 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- NCGJACBPALRHNG-UHFFFAOYSA-M sodium;2,4,6-trinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NCGJACBPALRHNG-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Definitions
- the present disclosure is generally related to the fields of protein chemistry, formulation chemistry, enzymology, rheology, physical chemistry and the like.
- the disclosure is related to stabilized protein compositions and formulations thereof.
- the disclosure is related to storage stable protein compositions and formulations thereof.
- the disclosure is related to one or more freezing point depressed solid matrix (FPDSM) systems, melt granulation methods thereof and formulations thereof, wherein the FPDSM system encapsulates and stabilizes the protein compositions thereof, during the melt granulation process and subsequent storage.
- FPDSM freezing point depressed solid matrix
- proteins such as enzymes, transport proteins, structural proteins, defense proteins, regulatory proteins, receptor proteins, and the like have many remarkable biological properties, they are all subject to denaturation and degradation at elevated temperatures, and loss of activity over time at ambient temperature.
- proteins e.g., enzymes
- proteins can lose activity as result of proteolysis, unfolding, misfolding, aggregation, thermal instability, thermal stress, mechanical stress, sub-optimal buffer conditions, pH and the like.
- One particular factor that limits the lifetime (activity) of a protein is its susceptibility to enzymatic and non-enzymatic chemical reactions which degrade the protein.
- proteins e.g., enzymes
- proteins are subject to various forms of non-enzymatic denaturation and degradation including, but not limited to, unfolding, oxidative degradation of cysteine and methionine sulfur atoms, the deamidation of glutamine and asparagine residues, peptide-bond hydrolysis, cross-linking reactions between the protein amino groups and natural reducing sugars, and the like.
- Other factors influencing protein degradation and/or protein conformational stability include, but are not limited to, conditions such as temperature, pH, salt concentration, water activity, oxygen concentration, AG of folded versus unfolded protein, solvent/buffer systems, pressure, electromagnetic radiation (e.g., uv light), molecular contaminants, microbial contaminants, and the like.
- protein denaturation, degradation, protein stability and/or protein activity are significantly influenced by the temperatures at which the protein is expressed, produced, formulated, recovered, stored, used and the like.
- the net free energy (AG) stabilizing a folded versus unfolded protein in an aqueous solution at 25°C is generally about 5-15 kcal/mol, which is approximately the amount energy needed to dissociate (break) about one to three non- covalent protein (intramolecular) interactions (e.g., electrostatic, Van der Walls, H-bonding).
- the stability (and activity) of a typical industrial enzyme such as a protease or amylase (e.g., for use in a laundry or dish cleaning) relates to the entire life cycle of the enzyme, which includes production (e.g., fermentation, downstream processing and formulation), distribution (e.g., transport and storage) and the final application/end-use (e.g., see, Misset, 1992; Chotani et al, 2017; Garske etal, 2017).
- the production phase of an enzyme can generally be subdivided into three processing steps, which include but are not limited to, (i) fermentation of the production organism (host cell) wherein the enzyme is either secreted into the culture medium or the host cells lysed to recover the enzyme, (ii) downstream processing of the fermentation broth (e.g., protein purification methods such as precipitation, ultrafiltration, chromatography, spray drying, etc.) to yield either a liquid or solid enzyme composition, and (iii) formulation of the enzyme composition to yield optimal performance and maximal stability of the final enzyme product.
- the formulated enzyme product is (iv) distributed by transportation and often stored at temperatures around 20°-39°C for a period time before (v) the final end use/application. It therefore becomes evident that such industrial enzymes are subjected to numerous environmental insults throughout their chain of production, formulation and final storage thereafter.
- WO2014/131906 provides Example 17, "Protein stabilization in animal tissue samples", wherein mouse liver was added to molten choline chloride/trifluoroacetamide (1 :2) or PBS buffer (control) and incubated at 24°C for up to 18 days prior to protein extraction.
- the present disclosure is directed to stable solid protein compositions, formulations thereof and melt granulation methods and compositions thereof, wherein the solid protein of interest (POI) is first dispersed in a molten (FPDSM) solvent system of the disclosure at an elevated temperature (i.e., between 40°C to about 100°C) and then subsequently cooled and solidified (i.e., about 20°C to 40°C ), such that the POI is entrapped in a "freezing point depressed solid matrix" (FPDSM) in its solid state.
- FPDSM molten
- a FPDSM composition of the disclosure comprises at least two FPDSM components, wherein each single (FPDSM) component of the FPDSM composition does not melt below 100°C (e.g., see Table 1, FPDSM Component Melting Points), and optionally further comprising water, wherein the FPDSM composition is a solid at a temperature between about 20°C to 40°C.
- molten solvent systems for solubilizing or stabilizing proteins
- maintenance of the composition in the "liquid state” e.g., for purposes such as extraction of the POI, solubilization of the POI, biocatalysis using solubilized enzymes, and the like.
- the present disclosure is directed to molten solvent systems (i.e., a FPDSM system of the disclosure) wherein a POI is embedded (e.g., entrapped) within the solvent system as it solidifies, such that the POI is immobilized and thereby not immediately available as a biocatalyst or reactant.
- FPDSM molten solvent system
- FPDSM molten solvent system
- Applicant discovered herein that it is not necessary to maintain specific molar ratios of the FPDSM components in order to achieve the desired properties of the instant disclosure, namely providing a molten solvent system (FPDSM) formulation wherein the POI is stable prior to solidification of the molten (FPDSM) system, and upon solidification of the FPDSM system, forms a solid matrix composition thereof useful for encapsulating, delivering and stabilizing enzymes at a temperature between about 20°C to 40°C.
- thermally labile proteins e.g., enzymes
- can retain most of their activity i.e. at least about 70% of their activity
- a surprising advantage of the present disclosure is that functional proteins (e.g., enzymes) suspended within the FPDSM can survive during suspension in the molten FPDSM, thereby maintaining high recovery of functional protein conformation and enzymatic activity, e.g., at least 70% recovery of initial enzyme activity, after being subjected to high temperatures (i.e., temperatures which usually denature most proteins; e.g., temperatures as high as 80 ° C, 90 ° C or 100 ° C) for periods of at least one minute to five minutes, prior to subsequent cooling and solidification from a melt (e.g., in a melt granulation process).
- high temperatures i.e., temperatures which usually denature most proteins; e.g., temperatures as high as 80 ° C, 90 ° C or 100 ° C
- the high recovery of active enzyme has been demonstrated for compositions that include water up to 10% w/w.
- the FPDSM (entrapped) enzyme compositions of the disclosure demonstrate excellent storage stability at room temperature (20°C-25°C)
- the instant disclosure addresses such long felt and unmet needs for methods, formulations, including granular formulations and compositions thereof which mitigate protein degradation, instability and/or inactivation, including such methods, formulations and compositions which mitigate the degradation and/or loss of activity of solid protein formulations which are stored for a period of time (i.e., hours, days, weeks, months) before their end use.
- the present disclosure is directed to stable solid protein compositions, formulations thereof and methods thereof.
- the disclosure is directed to methods for preparing/formulating one or more "freezing point depressed solid matrix" (FPDSM) systems which stabilize solid protein compositions.
- FPDSM freezing point depressed solid matrix
- the disclosure is directed to methods for inhibiting the degradation of solid protein compositions formulated with one or more FPDSM systems of the disclosure.
- the disclosure is directed to a solid enzyme formulation comprising a freezing point depressed solid matrix (FPDSM) system and a solid enzyme composition entrapped therein, wherein the FPDSM system comprises at least two distinct FPDSM components which at least two distinct FPDSM components do not melt at a temperature below 100°C until combined, wherein the combined FPDSM system is a liquid at a temperature between 40°C to about 100°C and a solid at a temperature between about 20°C to 40°C, wherein recovery of the active enzyme from the solidified FPDSM system is at least 70% active enzyme relative to the activity of the solid enzyme composition.
- the at least two component FPDSM further comprises up to 10% (w/w) water.
- the water content is about 0.05% to 10% w/w. In certain embodiments, the water content is about 1% to about 10% w/w, about 2% to about 10% w/w, about 3% to about 10% w/w, about 4% to about 10% w/w, or about 5% to about 10% w/w.
- the FPDSM system comprises a combination of at least two components selected from the group consisting of ammonium chloride, choline chloride, betaine, betaine hydrochloride, citric acid, malonic acid, tartaric acid, fructose, sucrose, glucose, lactose, maltose, urea and sorbitol.
- the at least two components of the FPDSM system are combined at a molar ratio ranging from about 1 : 10 to about 10: 1, wherein the combined molar ratio of the FPDSM system components are in a liquid state at a temperature between 40°C to about 100°C, and a solid at a temperature between about 20°C to 40°C.
- the enzyme retains at least 85% enzymatic activity after twenty-four (24) hours of storage at 25°C. In other embodiments, the enzyme retains at least 95% enzymatic activity after twenty -four (24) hours of storage at 25 °C. In certain other embodiments, the enzyme retains at least 99% enzymatic activity after twenty -four (24) hours of storage at 25°C. In yet another embodiment, the enzyme retains at least 80% enzymatic activity after seven (7) days of storage at 25 °C. In certain other embodiments, the enzyme retains at least 75% enzymatic activity after twenty-eight (28) days of storage at 25°C.
- the FPDSM formulated solid enzyme composition retains a higher enzymatic activity than an unformulated solid enzyme composition, wherein both the FPDSM formulated enzyme and the solid enzyme composition are held at the same temperature for the same amount of time before enzymatic activity is assayed.
- the enzyme is selected from the group consisting of acetyl esterases, aryl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carbonic anhydrases, carboxypeptidases, catalases, cellulases, chitinases, chymosins, cutinases, deoxyribonucleases, epimerases, esterases, a-galactosidases, ⁇ -galactosidases, a-glucanases, glucan lysases, endo- -glucanases, glucoamylases, glucose oxidases, a-glucosidases, ⁇ -glucosidases, glucuronidases, glycosyl hydrolases, hemicellulases, hexose oxidases, hydrolases, invertases, isome
- the FPDSM system comprises choline chloride and citric acid at a molar ratio between about 1:2 (choline chloride/citric acid) to about 2: 1 (choline chloride/citric acid).
- the FPDSM system comprises choline chloride and sorbitol at a molar ratio between about 2: 1 (choline chloride/sorbitol) to about 3: 1 (choline chloride/sorbitol).
- the FPDSM system comprises anhydrous betaine and urea at a molar ratio between about 1 : 1 (betaine/urea) to about 1 :4 (betaine/urea).
- the FPDSM system comprises ammonium chloride and urea at a molar ratio between about 1 :2 (ammonium chloride/urea) to about 1 :3 (ammonium chloride/urea).
- the FPDSM system comprises at least two different enzymes.
- the solid enzyme composition is a spray dried enzyme, a lyophilized enzyme, a precipitated enzyme, a crystalized enzyme, a spray cooled enzyme, spray chilled enzyme or a spray granulated enzyme.
- the FPDSM formulated solid enzyme comprises a solid form selected from a solid enzyme pellet, a solid enzyme granule, a solid enzyme powder, a solid enzyme film and a solid enzyme extrudate.
- the disclosure is related to a solid enzyme composition homogenously distributed and entrapped in a FPDSM system formulation of the disclosure.
- the disclosure is directed to a method for stabilizing a solid enzyme composition from loss of activity, the method comprising (a) selecting and preparing a FPDSM system comprising at least two distinct FPDSM system components and optionally up to 10% water, wherein the FPDSM system components are selected such that when combined and heated, form a liquid at a temperature between 40°C to about lOOC, and when subsequently cooled, form a solid at a temperature between about 20°C to 40°C, (b) adding and mixing a solid enzyme composition to the FPDSM system of step (a) at a temperature higher than 40°C and lower than about 100°C, and (c) lowering the temperature of the step (b) mixture to a temperature between about 20°C to 40°C, wherein the FPDSM system solidifies to form a solid FPDSM system that entraps and encapsulates the enzyme.
- the recovery of the FPDSM formulated enzyme relative to the recovery of solid enzyme composition is at least 70%.
- the enzyme retains at least 85% enzymatic activity after twenty -four (24) hours of storage at 25 °C.
- the enzyme retains at least 95% enzymatic activity after twenty-four (24) hours of storage at 25 °C.
- the enzyme retains at least 99% enzymatic activity after twenty-four (24) hours of storage at 25 °C.
- the enzyme retains at least 80% enzymatic activity after seven (7) days of storage at 25°C.
- the enzyme retains at least 75% enzymatic activity after twenty-eight (28) days of storage at 25°C.
- the FPDSM formulated solid enzyme composition retains a higher enzymatic activity than an unformulated solid enzyme composition, wherein both the FPDSM formulated enzyme and the solid enzyme composition are stored at the same temperature for the same amount of time before enzymatic activity is assayed.
- the FPDSM system comprises a combination of at least two components selected from the group consisting of ammonium chloride, choline chloride, betaine, betaine hydrochloride, citric acid, malonic acid, tartaric acid, fructose, sucrose, glucose, lactose, maltose, urea and sorbitol.
- the FPDSM system comprises a combination selected from the group consisting of urea/lactose, urea/glucose, urea/maltose, urea/fructose, urea/ammonium chloride, urea/betaine, urea/betaine hydrochloride, urea/choline chloride, betaine/glucose, betaine/fructose, betaine/lactose, betaine/citric acid, betaine/sucrose, choline chloride/glucose, choline chloride/malonic acid, choline chloride/ tartaric acid, choline chloride/citric acid, choline chloride/ sorbitol, citric acid/glucose and citric acid/maltose.
- urea/lactose urea/glucose
- urea/maltose urea/fructose
- urea/ammonium chloride ure
- two components of the FPDSM system are combined at a molar ratio ranging from about 1 : 10 to about 10: 1, wherein the combined molar ratio of the FPDSM system components are in a liquid state at a temperature between 40°C to about 100°C, and a solid at a temperature between about 20°C to 40°C.
- the FPDSM system comprises choline chloride and citric acid at a molar ratio between about 1 :2 (choline chloride/citric acid) to about 2: 1 (choline chloride/citric acid).
- the FPDSM system comprises choline chloride and sorbitol at a molar ratio between about 2: 1 (choline chloride/sorbitol) to about 3: 1 (choline chloride/sorbitol).
- the FPDSM system comprises anhydrous betaine and urea at a molar ratio between about 1 : 1 (betaine/urea) to about 1 :4 (betaine/urea).
- the FPDSM system comprises ammonium chloride and urea at a molar ratio between about 1:2 (ammonium chloride/urea) to about 1 :3 (ammonium chloride/urea).
- the FPDSM system comprises betaine and glucose at a molar ratio of about 5:2 (betaine/glucose) and about 0.05% to 10% weight water. In another embodiment, the FPDSM system comprises betaine and urea at a molar ratio of about 1 : 1 (betaine/glucose) and about 0.05% to 10% weight water. In other embodiments of the method, the FPDSM system comprises urea and glucose at a molar ratio of about 3: 1 (urea/glucose) and about 0.05% to 10% weight water.
- the FPDSM system comprises urea and maltose at a molar ratio of about 6: 1 (urea/maltose) and about 0.05% to 10% weight water. In yet other embodiments, the FPDSM system comprises urea and lactose at a molar ratio of about 6: 1 (urea/lactose) and about 0.05% to 10% weight water. In another embodiment, the FPDSM system comprises urea and lactose at a molar ratio of about 9: 1 (urea/lactose) to about 1.5: 1 (urea/lactose) and about 4.0% to 6.0% weight water. In other embodiments of the method, the water content is about 0.05% to 10% w/w. In certain other embodiments, the water content is about 5% to 10% w/w.
- the enzyme is selected from the group consisting of acetyl esterases, aryl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carbonic anhydrases, carboxypeptidases, catalases, cellulases, chitinases, chymosins, cutinases, deoxyribonucleases, epimerases, esterases, a-galactosidases, ⁇ -galactosidases, a-glucanases, glucan lysases, endo- -glucanases, glucoamylases, glucose oxidases, a-glucosidases, ⁇ -glucosidases, glucuronidases, glycosyl hydrolases, hemicellulases, hexose oxidases, hydrolases, invertases, isomerase
- the FPDSM system comprises at least two different enzymes.
- the solid enzyme composition is a spray dried enzyme, a lyophilized enzyme, a precipitated enzyme, a crystalized enzyme, a spray cooled enzyme, spray chilled enzyme or a spray granulated enzyme.
- the solidified FPDSM system of step (c) comprises a solid form selected from a solid pellet, a solid granule, a solid powder, a solid film and a solid extrudate.
- the disclosure is related to a solid enzyme composition homogenously distributed and entrapped in a FPDSM system prepared by a method of the disclosure.
- the disclosure is related to a method for inhibiting the degradation of a solid enzyme composition stored for at least twenty-four hours at 25 °C, the method comprising (a) selecting and preparing a FPDSM system comprising at least two distinct FPDSM system components and optionally up to 10% water, wherein the FPDSM system components are selected such that when combined and heated, form a liquid at a temperature between 40°C to about 100°C, and when subsequently cooled, form a solid at a temperature between about 20°C to 40°C, (b) adding and mixing a solid enzyme composition to the FPDSM system of step (a) at a temperature higher than 40°C and lower than about 100°C, and (c) lowering the temperature of the step (b) mixture to a temperature between about 20°C to 40°C, wherein the FPDSM system solidifies to form a solid FPDSM system that entraps and encapsulates the enzyme.
- the recovery of the FPDSM formulated enzyme relative to the recovery of solid enzyme composition is at least 70%.
- the enzyme retains at least 85% enzymatic activity after twenty-four (24) hours of storage at 25°C.
- the enzyme retains at least 95% enzymatic activity after twenty-four (24) hours of storage at 25 °C.
- the enzyme retains at least 99% enzymatic activity after twenty-four (24) hours of storage at 25°C.
- the enzyme retains at least 80% enzymatic activity after seven (7) days of storage at 25°C.
- the enzyme retains at least 75% enzymatic activity after twenty-eight (28) days of storage at 25°C.
- the FPDSM formulated solid enzyme composition retains a higher enzymatic activity than an unformulated solid enzyme composition, wherein both the FPDSM formulated enzyme and the solid enzyme composition are stored at the same temperature for the same amount of time before enzymatic activity is assayed.
- the FPDSM system comprises a combination of at least two components selected from the group consisting of ammonium chloride, choline chloride, betaine, betaine hydrochloride, citric acid, malonic acid, tartaric acid, fructose, sucrose, glucose, lactose, maltose, urea and sorbitol.
- the FPDSM system comprises a combination selected from the group consisting of urea/lactose, urea/glucose, urea/maltose, urea/fructose, urea/ammonium chloride, urea/betaine, urea/betaine hydrochloride, urea/choline chloride, betaine/glucose, betaine/fructose, betaine/lactose, betaine/citric acid, betaine/sucrose, choline chloride/glucose, choline chloride/malonic acid, choline chloride/ tartaric acid, choline chloride/citric acid, choline chloride/ sorbitol, citric acid/glucose and citric acid/maltose.
- urea/lactose urea/glucose
- urea/maltose urea/fructose
- urea/ammonium chloride ure
- two components of the FPDSM system are combined at a molar ratio ranging from about 1 : 10 to about 10: 1, wherein the combined molar ratio of the FPDSM system components are in a liquid state at a temperature between 40°C to about 100°C, and a solid at a temperature between about 20°C to 40°C.
- the FPDSM system comprises choline chloride and citric acid at a molar ratio between about 1:2 (choline chloride/citric acid) to about 2: 1 (choline chloride/citric acid).
- the FPDSM system comprises choline chloride and sorbitol at a molar ratio between about 2: 1 (choline chloride/sorbitol) to about 3: 1 (choline chloride/sorbitol).
- the FPDSM system comprises anhydrous betaine and urea at a molar ratio between about 1 : 1 (betaine/urea) to about 1 :4 (betaine/urea).
- the FPDSM system comprises ammonium chloride and urea at a molar ratio between about 1 :2 (ammonium chloride/urea) to about 1 :3 (ammonium chloride/urea).
- the FPDSM system comprises betaine and glucose at a molar ratio of about 5:2 (betaine/glucose) and about 0.05% to 10% weight water.
- the FPDSM system comprises betaine and urea at a molar ratio of about 1 : 1 (betaine/glucose) and about 0.05% to 10% weight water.
- the FPDSM system comprises urea and glucose at a molar ratio of about 3: 1 (urea/glucose) and about 0.05% to 10% weight water. In certain other embodiments, the FPDSM system comprises urea and maltose at a molar ratio of about 6: 1 (urea/maltose) and about 0.05% to 10% weight water. In another embodiment, the FPDSM system comprises urea and lactose at a molar ratio of about 6: 1 (urea/lactose) and about 0.05% to 10% weight water.
- the FPDSM system comprises urea and lactose at a molar ratio of about 9: 1 (urea/lactose) to about 1.5: 1 (urea/lactose) and about 4.0% to 6.0% weight water.
- the FPDSM system water content is about 0.05% to 10% w/w. In another embodiment, the water content is about 5% to 10% w/w.
- the enzyme is selected from the group consisting of acetyl esterases, aryl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carbonic anhydrases, carboxypeptidases, catalases, cellulases, chitinases, chymosins, cutinases, deoxyribonucleases, epimerases, esterases, a-galactosidases, ⁇ -galactosidases, a-glucanases, glucan lysases, endo- -glucanases, glucoamylases, glucose oxidases, a-glucosidases, ⁇ -glucosidases, glucuronidases, glycosyl hydrolases, hemicellulases, hexose oxidases, hydrolases, invertases, is
- the FPDSM system comprises at least two different enzymes.
- the solid enzyme composition is a spray dried enzyme, a lyophilized enzyme, a precipitated enzyme, a crystalized enzyme, a spray cooled enzyme, spray chilled enzyme or a spray granulated enzyme.
- the solidified FPDSM system of step (c) comprises a solid form selected from a solid pellet, a solid granule, a solid powder, a solid film and a solid extrudate.
- the disclosure is related to a solid enzyme composition homogenously distributed and entrapped in a FPDSM system prepared by a method of the disclosure.
- Figure 1 shows the viscosity (cP) of a two-component FPDSM system comprising betaine and urea at 95°C, plotted as a function of the betaine mole fraction.
- Figure 2 shows the percent (%) recovery of a subtilisin protease, as the percentage of residual enzyme activity remaining after addition to a molten FPDSM composition, with subsequent solidification at room temperature (21° C in this particular case).
- the percent residual activity is plotted as a function of water added to a FPDSM system set forth in Table 3.
- Figure 3 shows a plot of percent (%) recovery of a subtilisin protease, as a function of the mixing temperature (°C) used to entrap the enzyme in a FPDSM system set forth in Table 2 of the specification.
- the compositions of Figure 3 are the same as those of Figure 2; accordingly, the composition with higher percentages of water had lower melting points.
- the present disclosure is generally related to solid protein compositions and specific formulations thereof which stabilize the solid protein compositions. More specifically, in certain embodiments, the disclosure is directed to formulations which stabilize solid protein compositions and concomitantly mitigate or inhibit certain environmental factors associated with enzymatic and non-enzymatic protein degradation. More particularly, Applicant of the instant disclosure has discovered that certain combinations (i.e., mixtures) of "solvent components" in specified ranges of molar ratios are particularly suitable for mitigating protein degradation, protein instability and/or protein inactivation, most particularly, thermally-induced protein inactivation.
- Thermally-induced protein inactivation can arise by well-known biophysical and biochemical processes such as protein unfolding, protein aggregation, oxidation, glycation, deamidation, and the like.
- Storage-stable protein formulations can be produced using a variety of protein formulation, particle formation, and drying processes.
- certain embodiments of the disclosure are directed to storage stable solid protein compositions (e.g., a lyophilized solid protein composition, a spray dried solid protein composition, a spray cooled solid protein composition, a spray chilled solid protein composition, a spray granulated solid protein composition and the like), formulations thereof and methods thereof, wherein the solid protein of interest (POI) is entrapped in a "freezing point depressed solid matrix" (FPDSM) system of the disclosure.
- POI solid protein of interest
- FPDSM freezing point depressed solid matrix
- the disclosure is directed to methods for preparing/formulating one or more "freezing point depressed solid matrix" (hereinafter "FPDSM”) systems which encapsulate solid protein compositions.
- FPDSM freezing point depressed solid matrix
- the disclosure is related to one or more solid protein compositions formulated in a FPDSM system described herein.
- the disclosure is related to methods for inhibiting the degradation of solid protein compositions formulated with one or more FPDSM systems described herein.
- the disclosure is related to stable solid protein compositions, formulations thereof, granulation processes thereof and methods thereof, wherein the solid protein of interest is distributed in a (molten liquid) FPDSM system of the disclosure, wherein each individual (FPDSM system) component is a solid that does not melt below 100°C, wherein the combined (molten liquid) FPDSM system solidifies and entraps the protein of interest at a temperature of about 20°C to 40°C.
- certain embodiments are directed to one or more proteins of interest (e.g., an enzyme) formulated in a tunable FPDSM system of the disclosure, wherein the FPDSM system is tuned to be a liquid at a temperature between 40°C to about 100°C, and a solid at a temperature between about 20°C to 40°C.
- proteins of interest e.g., an enzyme
- the disclosure is related to solid protein compositions of interest (e.g., a protease, an amylase, a glucoamylase, a lipase, etc.) formulated in a tunable FPDSM system of the disclosure, wherein such FPDSM formulations mitigate the degradation and/or loss of activity of the solid protein composition, particularly solid protein compositions which are stored for a period of time (i.e., hours, days, weeks, months) before their end use.
- solid protein compositions of interest e.g., a protease, an amylase, a glucoamylase, a lipase, etc.
- a “freezing point depressed solid matrix” (abbreviated herein as, "FPDSM”), a freezing point depressed solid matrix “system” or a “FPDSM system” may be used interchangeably.
- a “FPDSM system” comprises at least two (2) distinct FPDSM components, wherein each distinct (FPDSM system) component individually does not melt below 100°C, yet in combination the at least two (2) distinct FPDSM components melt at a temperature between 40°C to about 100°C.
- a “FPDSM system” of the disclosure, comprising at least two (2) distinct FPDSM components further comprises up to about 10% (w/w) water.
- a "distinct” FPDSM system component or simply a “FPDSM component”, as used in phrases such as a "distinct FPDSM system component", a “distinct FPDSM solvent component”, “individual FPDSM component” and the like includes, but is not limited to, FPDSM components selected from the group consisting of ammonium chloride (NH4CI), choline chloride, betaine ( ⁇ , ⁇ , ⁇ ,- trimethylglycine), betaine hydrochloride, citric acid, malonic acid, tartaric acid, sorbitol, sucrose, fructose, glucose, lactose, maltose, urea, and the like.
- NH4CI ammonium chloride
- choline chloride betaine ( ⁇ , ⁇ , ⁇ ,- trimethylglycine)
- betaine hydrochloride citric acid, malonic acid, tartaric acid
- sorbitol sucrose, fructose, glucose, lactose, maltose, urea, and
- a "solid protein”, a “solid protein composition”, a “solid enzyme composition”, and the like specifically refer to a protein composition in its solid dried state (e.g., by means of lyophilization, spray drying, crystallization, spray cooling, spray chilling, spray granulated, and the like), in contrast to a "liquid protein composition", which liquid protein compositions are substantially hydrated (dissolved) in water or an aqueous buffer thereof.
- solid enzyme a "solid” protein, a “solid” enzyme composition and the like
- dry protein a “dry” enzyme, a “dried” enzyme, a “dried” protein, a “dried” enzyme composition and the like.
- protein will be used hereinafter when referring to a “solid protein” composition of the disclosure.
- solid protein composition of the disclosure.
- molten solvent system particularly refers to a FPDSM system of the disclosure, wherein the at least two (2) FPDSM components have been combined and mixed at a temperature between 40°C to about 100°C, wherein the FPDSM system has been tuned to be in a liquid state at a temperature between 40°C to about 100°C (i. e., melt below about 100°C).
- a “solid” or “solidified” FPDSM system of the disclosure particularly refers to the same FPDSM system, wherein the FPDSM system has been cooled to a temperature between about 20°C to 40°C, such that the FPDSM system solidifies, thereby entrapping and encapsulating the solid protein composition therein.
- room temperature means a temperature between about 20°C to about 28°C.
- ambient temperature means a temperature between about 20°C to about 40°C.
- enzyme recovery is calculated as the weight percentage of active enzyme in the solidified FPDSM material relative to the enzyme activity in the initial solid spray dried enzyme powder.
- a “stable” enzyme composition” e.g., as used in phrases such as “a stable enzyme composition”, “a storage stable enzyme composition” or “a FPDSM stabilized enzyme" particularly refers to a solid enzyme composition formulated in a FPDSM system the disclosure.
- the enzymatic activity of the "stable" (FPDSM formulated) enzyme composition is relative to (vis-a-vis) the activity of the same (unformulated) enzyme composition (e.g., a solid enzyme, spray-dried control) when the solid enzyme (spray -dried control) is assayed (measured) under the same conditions.
- a solid enzyme, spray-dried control e.g., a solid enzyme, spray-dried control
- weight percent or “weight %” are abbreviated hereinafter “wt%” or “% w/w”.
- the term protein or enzyme "melting temperature” (assuming two-state protein folding (F U)), is the denaturation midpoint “T m ", which is defined as the temperature at which both the folded (F) and unfolded (U) states are equally populated at equilibrium.
- a "protein of interest” may be abbreviated as "POI", wherein a POI of the disclosure includes, but is not limited to, enzymes, transport proteins, structural proteins, defense or immune related proteins (cytokines; e.g., IL-12), regulatory proteins, receptor proteins, immunoglobulins, cytokines (e.g., IL- 12), and the like.
- cytokines e.g., IL-12
- cytokines e.g., IL-12
- cytokines e.g., IL-12
- immunoglobulins cytokines
- cytokines e.g., IL- 12
- a POI according to the instant disclosure is any solid protein composition contemplated for formulation and stabilization thereof in a FPDSM system of the disclosure.
- polypeptide and “protein” are used interchangeably and include reference to polymers comprising amino acid residues linked by peptide bonds.
- the conventional one (1) letter or three (3) letter codes for amino acid residues are used
- polypeptide amino acid polymers in which one or more amino acid residues are an artificial chemical analog of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
- the terms also encompass amino acid polymers that have been modified naturally or by intervention (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification).
- polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
- a "variant" protein refers to a protein that is derived from a parent (or reference) protein by the substitution, addition, or deletion of one or more amino acids, typically by recombinant DNA techniques. Variant proteins may differ from a parent protein by a small number of amino acid residues and may be defined by their level of primary amino acid sequence homology/identity with a parent (reference) protein.
- the disclosure are directed to one or more storage stable protein compositions, wherein the protein composition is distributed and encapsulated (entrapped) within an FPDSM system, wherein the FPDSM system comprises at least two FPDSM components (each of which individual FPDSM components does not melt below 100°C), wherein the FPDSM system is fine tuned to be a molten liquid at a temperature between 40°C to about 100°C, and a solid at a temperature between about 20°C to 40°C.
- the processes for producing the FPDSM compositions of the disclosure can be generically described as melt solidification or melt granulation processes. More particularly, in all of these processes, a dry form of the protein (e.g., produced by processes such as lyophilization, spray drying, crystallization, precipitation, spray chilling and the like) is suspended in the molten (liquid) FPDSM solvent system and subsequently solidified at ambient temperatures (e.g., about 20°C to 40°C).
- the resulting solidified formulations can be of any size or shape (i.e., monoliths, tablets, granules or powders).
- melt solidification is melt granulation.
- the molten FPDSM system in which the POI is suspended
- the molten FPDSM system is atomized or formed into particles or granules, which are flowable and provide protection to the POI.
- Granules are typically particles with diameters between about 50 microns and 1000 microns, or as large as 5000 microns.
- melt granulation processes included spray cooling, spray chilling, spinning disk atomization, melt extrusion, and the like.
- Examples of individual components suitable for combining in a FPDSM system of the disclosure are listed below in Table 1. Note that the melting point (in some cases, a decomposition point) of each individual component is greater than 100°C (i.e., none of these individual (distinct) components melts below 100°C). However, as stated above and further discussed below, when the components are combined in mixtures in certain ratios (and/or with the addition of up to 10% w/w water), the resulting (combined) FPDSM systems will melt at a temperature between 40°C to about 100°C, and yet will solidify at a temperature between about 20°C to 40°C.
- a protein of interest is formulated in a tunable FPDSM system of the disclosure, wherein the POI is combined (added) with a FPDSM system at a temperature between 40°C to about 100°C.
- the combined FPDSM/POI formulation is subsequently cooled to a temperature between about 20°C to 40°C (/ ' . e. , a temperature at which the FPDSM system is a solid), wherein the FPDSM encapsulates (entraps) the protein composition within a solid matrix as the FPDSM system transitions from a liquid state to a solid state during the cooling process.
- a protein composition is formulated in a FPDSM system of the disclosure and encapsulated by cooling the FPDSM system as generally described above, wherein the encapsulated POI is substantially stabilized against various forms of environmental protein degradation. More particularly, certain embodiments are related to protein compositions formulated in a FPDSM system of the disclosure, wherein the FPDSM encapsulated composition may be stored at temperatures up to about 40°C or less for a period of time (e.g., an hour, a day, a week, a month, etc.) prior the end use of the particular protein (POI) composition.
- a period of time e.g., an hour, a day, a week, a month, etc.
- an elegant benefit of the tunable FPDSM systems of the instant disclosure, and more particularly the protein compositions formulated therein (and granules thereof), is that the protein composition (or granules thereof) is readily reconstituted for end use by dilution of the solid FPDSM composition in water (or an aqueous buffered solvent).
- a protein composition is formulated in a FPDSM system of the disclosure, wherein the FPDSM encapsulated composition (or granules thereof) may be held at temperatures up to about 40°C or less for a period of time prior the end use of the particular protein composition, with minimal loss of protein activity thereof.
- a FPDSM system of the disclosure comprises at least two (2) distinct FPDSM components.
- a FPDSM system of the disclosure may additionally comprise up to about 10% (w/w) water.
- such distinct FPDSM components are selected from the group consisting of ammonium chloride (NH4CI), choline chloride, betaine ( ⁇ , ⁇ , ⁇ ,-trimethylglycine), betaine hydrochloride, citric acid, malonic acid, tartaric acid, sorbitol, sucrose, fructose, glucose, lactose, maltose and urea.
- an at least two component FPDSM system comprises betaine and monosaccharide, wherein the monosaccharide is selected from the group consisting of glucose, galactose, fructose, mannose, erythrose, ribose, glyceraldehyde, dihydroxyacetone, glycerol, sorbitol, mannitol and dulcitol.
- any POI e.g., enzyme
- T m thermal denaturation profile and melting temperature
- optimal FPDSM systems are provided, wherein the protein composition is combined with the FPDSM system at temperatures between 40°C to about 100°C.
- T m of a protein is generally defined as the temperature at which both the folded (F) and unfolded (U) states are equally populated at equilibrium.
- a novel protein e.g., a novel enzyme or novel variant thereof
- a combination of more than one protein e.g., a combination of two different enzymes
- a denaturation profile and/or a protein melting temperature (T m ) profile may readily determine a denaturation profile and/or a protein melting temperature (T m ) profile using routine laboratory techniques and methods available in the art including, but not limited to, differential scanning calorimetry (DSC), circular dichroism (CD), fluorescence anisotropy (polarized light), Fourier transform infrared spectroscopy (FTIR), hydrophobic fluorophores, intrinsic (tryptophan) fluorescence lifetime changes, light scattering, ultracentrifugation sedimentation velocity analysis and the like.
- DSC differential scanning calorimetry
- CD circular dichroism
- fluorescence anisotropy polarized light
- FTIR Fourier transform infrared spectroscopy
- hydrophobic fluorophores intrinsic (tryptophan) fluorescence lifetime changes, light scattering, ultracentrifugation sedimentation velocity analysis and the like.
- subtilisin protease i.e., Properase ® enzyme
- FPDSM systems of the disclosure at elevated temperatures (e.g. 80-100°C), wherein it is generally known in the art that subtilisin proteases (e.g., including, but not limited to Properase ® ) are relatively unstable at temperatures of about 55°C and above.
- the water (e.g., up to about 10% w/w) in such FPDSM systems is sequestered, and hence less available than "free" water to interact with the POI in a manner that would lead to inactivation or other manifestations of irreversible structural destabilization.
- FIG. 2 of the disclosure demonstrates excellent enzyme recovery in the FDPSM at up to 10% w/w water, wherein it is possible that even more than 10% w/w water can be incorporated into the FDPSM without adverse impact on enzyme recovery.
- the melting point of a solid matrix suitable for the formulation of enzymes can be depressed, and thereby "tuned” to more enzyme or protein friendly temperatures, by means of the two levers of the instant disclosure comprising: (1) blending two or more solid components to form a FPDSM blend; and (2) incorporating water, to further depress the melting point.
- the compositions of the instant disclosure comprise FPDSM systems suitable for entrapping enzymes and thereby improving their recovery and stability.
- Certain embodiments of the disclosure are directed to one or more proteins of interest (e.g., an enzyme) formulated in a tunable FPDSM system of the disclosure, wherein the FPDSM system is tuned to be a liquid at temperatures of 40°C to about 100°C, and a solid at temperatures between about 20°C to 40°C. More particularly, in certain embodiments the disclosure is directed to a protein composition of interest formulated in a tunable FPDSM system of disclosure, wherein such FPDSM systems significantly mitigate the degradation and/or loss of activity of the protein composition, particularly such formulated protein compositions which are stored for a period of time (i.e., days, weeks, months) before their end use.
- a period of time i.e., days, weeks, months
- FPDSM system (solvent) components were screened at the indicated (component 1): (component 2) molar ratios specified in the Tables 2 and 3: ammonium chloride, choline chloride, betaine ( ⁇ , ⁇ , ⁇ ,-trimethylglycine), betaine hydrochloride, citric acid, malonic acid, tartaric acid, sorbitol, fructose, sucrose, glucose, lactose, maltose, urea and water.
- the FPDSM system components (Table 2 or Table 3) were screened in the Example 1 with the specific parameters that: (a) the combined FPDSM system components melt (form a liquid) at a temperature between 40°C to about 100°C (i.e., to mitigate thermal denaturation/inactivation of the protein) and (b) that the FPDSM system should quickly solidify at a temperature between about 20°C to 40 ° C, thereby quickly forming a robust solid matrix, suitable for encapsulation of proteins. As described in Example 2, the FPDSM systems meeting the aforementioned screening parameters were subsequently prepared/formulated with an active POI (i.e., a subtilisin protease).
- an active POI i.e., a subtilisin protease
- the POI formulations presented in Example 2 are FPDSM systems comprising added water (e.g. 5% w/w), wherein the following solvent component combinations were assessed: (i) anhydrous betaine/urea (1 : 1 mole ratio) and 5% (weight) water, and (ii) urea/lactose (6: 1 mole ratio) and 5% (weight) water.
- Example 2 FPDSM systems were assayed as described in Example 3, wherein the percent (%) recovered protease activity of the anhydrous betaine/urea (1 : 1 mole ratio) + 5% water formulation was 71.8% and the percent (%) recovered protease activity of the urea/lactose (6: 1 mole ratio) + 5% water was 87.3%. (e.g., see, Table 5)
- Example 4 the ability to fine tune such FPDSM systems are demonstrated in Example 4.
- certain FPDSM systems which did not melt (i.e., form a liquid) at a temperature feasible for formulating the subtilisin protease i.e., at a temperature of 40°C to about 100°C were re-formulated (i.e., fine-tuned) with the addition of water (e.g., up to about 10% w/w).
- Example 6 the ability to fine tune such FPDSM systems by the addition of a specified weight percent of water, thereby lowering the FPDSM system mixing temperature, significantly enhances the recovered protease activity of these formulations (e.g., see, Table 6, urea/ammonium chloride (1:4) + 10% water and betaine/urea (1 : 1) + 5% water).
- a comparison of the urea/glucose (1 : 1) + 5% water (FPDSM system) relative to the urea/glucose (1 : 1) + 10% water (FPDSM system) indicates that the water addition does not significantly reduce the mixing temperature going from 5% water (i.e., 80°C) to 10% water (i.e., 80°C), whereas the recovered protease activity from the same formulations indicate that the water in such FPDSM systems improves the recovery of active protease (e.g., the Properase ® relative residual activity of the urea/glucose (1 : 1) + 5% water (FPDSM system) was 79.7%, whereas the Properase ® relative residual activity of the urea/glucose (1 : 1) + 10% water (FPDSM system) increased to 93%).
- active protease e.g., the Properase ® relative residual activity of the urea/glucose (1 : 1) + 5% water (FPDSM
- Example 5 provides an exemplary analysis of the protease activity (i.e., Properase ® ) as a function of different mixing temperatures, which analysis is readily extended to other proteins of interest contemplated herein. For example, as shown in FIG. 3., there was an evident decrease in protease activity as the mixing temperature generally exceeded 80°C.
- protease activity i.e., Properase ®
- Example 6 and Example 7 of the disclosure further describe methods for granulating such protein encapsulated FPDSM systems, which protein/FPDSM system granules are particularly suitable for short- term or long-term storage thereof.
- Example 8 of the disclosure demonstrates the storage stability of such protein/FPDSM system formulations.
- a subtilisin protease was formulated in a FPDSM system of the disclosure, wherein the storage stability of the protease/FPDSM system formulation was evaluated at 25°C for a period of 28 days. More specifically, as presented in Table 7, the protease activity at days 7, 14, 21 and 28, remained well above 98% recovered activity. Furthermore, when compared to the activity of the control protease (i.e., spray dried protease) at days 7, 14, 21 and 28, the recovered protease activity of all FPDSM systems demonstrate that greater protease activity was maintained relative to the spray dried protease.
- the control protease i.e., spray dried protease
- Example 9 of the disclosure further describes a second POI (i.e., an amylase) formulated and stabilized in a FPDSM system of the disclosure. More particularly, Example 9 describes the maximum solubility of an a-amylase protein of interest in a choline chloride/urea (1 :2 ratio) FPDSM system (e.g., see, FIG. 4)
- the disclosure is directed to such FPDSM systems.
- the disclosure is related to one or more solid protein compositions formulated and stabilized in such FPDSM systems of the disclosure.
- the disclosure is related to storage stable solid enzyme compositions comprising a FPDSM system formulation disclosed herein, wherein such (FPDSM stabilized) solid enzyme compositions retain at least about 50% to 100% enzymatic activity after at least 24-hours of storage at 25°C. III. FPDSM Stabilized Proteins of Interest and Recovered Activity Thereof
- a protein of interest can be any endogenous or heterologous protein or a variant thereof.
- the protein can contain one or more disulfide bridges or is a protein whose functional form is a monomer or a multimer, i.e. , the protein has a quaternary structure and is composed of a plurality of identical (homologous) or non-identical (heterologous) subunits.
- certain embodiments of the disclosure are directed to one or more proteins of interest formulated in a protein stabilizing FPSDM system of the disclosure.
- a protein of interest is an enzyme, a hormone, a growth factor, a cytokine, an antibody, a receptor, and the like.
- a POI is an enzyme selected from acetyl esterases, aryl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carboxypeptidases, catalases, cellulases, chitinases, chymosin, cutinases, deoxyribonucleases, epimerases, esterases, a-galactosidases, ⁇ -galactosidases, a-glucanases, glucan lysases, endo- -glucanases, glucoamylases, glucose oxidases, a-glucosidases, ⁇ -glucosidases, glucuronidases, hemi
- a POI or a variant POI thereof is an enzyme selected from Enzyme Commission (EC) Number EC 1, EC 2, EC 3, EC 4, EC 5 or EC 6.
- a POI is an oxidoreductase enzyme, including, but not limited to, an EC 1 (oxidoreductase) enzyme selected from EC 1.10.3.2 (e.g., a laccase), EC 1.10.3.3 (e.g., L- ascorbate oxidase), EC 1.1.1.1 (e.g., alcohol dehydrogenase), EC 1.1 1.1.10 (e.g., chloride peroxidase), EC 1.11.1.17 (e.g., peroxidase), EC 1.1.1.27 (e.g., L-lactate dehydrogenase), EC 1.1.1.47 (e.g., glucose 1- dehydrogenase), EC 1.1.3.X (e.g., glucose oxidase), EC 1.1.3.10 (e.g., pyranose oxidase), EC 1.13.1 l .X (e.g., dioxygena
- l .X e.g., fatty acid reductase
- EC 1.2.1.10 e.g., acetaldehyde dehydrogenase
- EC 1.5.3.X e.g., fructosyl amine reductase
- EC 1.8.1.X e.g., disulfide reductase
- EC 1.8.3.2 e.g., thiol oxidase
- a POI is a transferase enzyme, including, but not limited to, an EC 2 (transferase) enzyme selected from EC 2.3.2.13 (e.g., transglutaminase), EC 2.4.
- an EC 2 (transferase) enzyme selected from EC 2.3.2.13 (e.g., transglutaminase), EC 2.4.
- l .X e.g., hexosyltransferase
- EC 2.4.1.40 e.g., altemasucrase
- EC 2.4.1.18 e.g., 1,4 alpha-glucan branching enzyme
- EC 2.4.1.19 e.g., cyclomaltodextrin glucanotransferase
- EC 2.4.1.2 e.g., dextrin dextranase
- EC 2.4.1.20 e.g., cellobiose phosphorylase
- EC 2.4.1.25 e.g., 4-alpha-glucanotransferase
- EC 2.4.1.333 e.g., 1,2-beta-oligoglucan phosphor transferase
- EC 2.4.1.4 e.g., amylosucrase
- EC 2.4.1.5 e.g., dextransucrase
- EC 2.4.1.69
- a POI is a hydrolase enzyme, including, but not limited to, an EC 3 (hydrolase) enzyme selected from EC 3.1.X.X (e.g., an esterase), EC 3.1.1.1 (e.g., pectinase), EC 3.1.1.14 (e.g., chlorophyllase), EC 3.1.1.20 (e.g., tannase), EC 3.1.1.23 (e.g., glycerol-ester acylhydrolase), EC 3.1.1.26 (e.g., galactolipase), EC 3.1.1.32 (e.g., phospholipase Al), EC 3.1.1.4 (e.g., phospholipase A2), EC 3.1.1.6 (e.g., acetylesterase), EC 3.1.1.72 (e.g., acetylxylan esterase), EC 3.1.1.73 (e.g., ferase).
- X e.g., serine-type carboxypeptidase
- EC 3.4.16.5 e.g., carboxypeptidase C
- EC 3.4.19.3 e.g., pyroglutamyl-peptidase I
- EC 3.4.21.X e.g., serine endopeptidase
- EC 3.4.21.1 e.g., chymotrypsin
- EC 3.4.21.19 e.g., glutamyl endopeptidase
- EC 3.4.21.26 e.g., prolyl oligopeptidase
- EC 3.4.21.4 e.g., trypsin
- EC 3.4.21.5 e.g., thrombin
- EC 3.4.21.63 e.g., oryzin
- EC 3.4.21.65 e.g., thermomycolin
- EC 3.4.21.80 e.g., strept
- X e.g., metalloendopeptidase
- EC 3.4.24.39 e.g., deuterolysin
- EC 3.4.24.40 v., serralysin
- EC 3.5.1.1 e.g., asparaginase
- EC 3.5.1.1 1 e.g., penicillin amidase
- EC 3.5.1.14 e.g., N-acyl-aliphatic-L-amino acid amidohydrolase
- EC 3.5.1.2 e.g., L-glutamine amidohydrolase
- EC 3.5.1.28 e.g., N-acetylmuramoyl-L- alanine amidase
- EC 3.5.1.4 e.g., amidase
- EC 3.5.1.44 e.g., protein-L-glutamine amidohydrolase
- EC 3.5.1.5 e.g., urease
- a POI is a lyase enzyme, including, but not limited to, an EC 4 (lyase) enzyme selected from EC 4.1.2.10 (e.g., mandelonitrile lyase), EC 4.1.3.3 (e.g., N-acetylneuraminate lyase), EC 4.2.1.1 (e.g., carbonate dehydratase), EC 4.2.2.- (e.g., rhamnogalacturonan lyase), EC 4.2.2.10 (e.g., pectin lyase), EC 4.2.2.22 (e.g., pectate trisaccharide-lyase), EC 4.2.2.23 (e.g. , rhamnogalacturonan endolyase) and EC 4.2.2.3 (e.g. , mannuronate-specific alginate lyase).
- an EC 4 (lyase) enzyme selected from
- a POI is an isomerase enzyme, including, but not limited to, an EC 5 (isomerase) enzyme selected from EC 5.1.3.3 (e.g. , aldose 1-epimerase), EC 5.1.3.30 (e.g., D-psicose 3- epimerase), EC 5.4.99.1 1 (e.g., isomaltulose synthase) and EC 5.4.99.15 (e.g., (l ⁇ 4)-a-D-glucan 1-a-D- glucosylmutase).
- an EC 5 (isomerase) enzyme selected from EC 5.1.3.3 (e.g. , aldose 1-epimerase), EC 5.1.3.30 (e.g., D-psicose 3- epimerase), EC 5.4.99.1 1 (e.g., isomaltulose synthase) and EC 5.4.99.15 (e.g., (l ⁇ 4)-a-D-glucan 1-a-D-
- a POI is a ligase enzyme, including, but not limited to, an EC 6 (ligase) enzyme selected from EC 6.2.1.12 (e.g., 4-coumarate: coenzyme A ligase) and EC 6.3.2.28 (e.g., L-amino- acid alpha-ligase).
- a POI of the disclosure is an industrial protease or amylase enzyme, which protease or amylase is stabilized and formulated in an FPDSM system of the disclosure.
- a POI is neutral protease (or "metalloproteases") or an alkaline (or "serine”) protease.
- Bacillus subtilisin proteins are exemplary serine proteases for use and stabilization in a FPDSM composition of the disclosure. More particularly, a wide variety of Bacillus subtilisins have been identified and sequenced, for example, subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin 147 and subtilisin 309 (e.g. , WO 1989/06279 and Stahl et al., 1984).
- variant proteases suitable for formulation in a FPDSM system of the disclosure such as PCT Publication Nos. WO1999/20770; WO1999/20726; WO1999/20769; WO1989/06279; U.S. RE34,606; U.S. Patent Nos. 4,914,031; 4,980,288; 5,208,158; 5,310,675; 5,336,611; 5,399,283; 5,441,882; 5,482,849; 5,631,217; 5,665,587; 5,700,676; 5,741 ,694; 5,858,757; 5,880,080; 6, 197,567 and 6,218,165.
- a POI is an amylase formulated and stabilized in an FPDSM system of the disclosure.
- amylase enzymes and variants thereof are known to one skilled in the art.
- International PCT Publication NO. WO2006/037484 and WO 2006/037483 describe variant a-amylases having improved solvent stability
- Publication No. WO 1994/18314 discloses oxidatively stable a-amylase variants
- Publication No. WO 1999/ 19467, WO2000/29560 and WO2000/60059 disclose Termamyl-like ⁇ -amylase variants, Publication No.
- WO2008/112459 discloses a- amylase variants derived from Bacillus sp. number 707
- Publication No. W01999/43794 discloses maltogenic a-amylase variants
- Publication No. WO1990/11352 discloses hyper-thermostable a-amylase variants
- Publication No. WO2006/089107 discloses ⁇ -amylase variants having granular starch hydrolyzing activity.
- a POI formulated and stabilized in a FPDSM system of the disclosure is a peptide, a peptide hormone, a growth factor, a clotting factor, a chemokine, a cytokine, a lymphokine, an antibody, a receptor, an adhesion molecule, a microbial antigen (e.g. , HBV surface antigen, HPV E7, etc.), variants thereof, fragments thereof and the like .
- Other types of proteins (or variants thereof) of interest may be those that are capable of providing nutritional value to a food or to a crop.
- Non-limiting examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g., a higher lysine content than a non-transgenic plant).
- certain embodiments are directed to FPDSM stabilized protein compositions. More particularly, certain embodiments are related to a solid enzyme composition stabilized in a FPDSM system of the disclosure.
- the activity of an enzyme of interest e.g., a protease
- the activity of an FPDSM formulated enzyme composition is measured after two (2) hours, after twelve (12) hours, after one (1) day, after seven (7) days, after twenty -one (21) days, etc. of storage at room temperature (RT; about 20-25°C).
- RT room temperature
- certain embodiments are related to recovered enzymatic activity of a FPDSM formulated enzyme composition which has been stored for a period of time prior to its end-use.
- assays There are various assays known to those of ordinary skilled in the art for detecting and measuring activity of proteins.
- proteases there are assays based on the release of acid-soluble peptides from casein or hemoglobin measured as absorbance at 280 nm or colorimetrically, using the Folin method (e.g., Bergmeyer et al, 1984).
- Other assays involve the solubilization of chromogenic substrates (see e.g., Ward, 1983).
- Other exemplary assays include succinyl-Ala-Ala-Pro-Phe-para-nitroanilide assay (SAAPFpNA) and the 2,4,6-trinitrobenzene sulfonate sodium salt assay (TNBS assay).
- SAAPFpNA succinyl-Ala-Ala-Pro-Phe-para-nitroanilide assay
- TNBS assay 2,4,6-trinitrobenzene sulfonate sodium salt assay
- Applicant screened various solvent components (see, Table 1) to identify solvent component mixtures (see, Tables 2 and 3) meeting specific pre-determined parameters which are relevant to the stability and formulation requirements of one or more protein compositions of the disclosure.
- the solvent component mixtures were screened for solvent component mixtures having melting points lower than 100°C, and an ability to solidify at a temperature above 20°C.
- Other considerations for solvent component mixtures may include suitable viscosity and non- hygroscopic behavior.
- Viscosity A Brookfield viscometer equipped with Spindle 18 was used to determine the viscosity of the betaine/urea compositions at different molar ratios. About Ten (10) grams of each composition was placed in the sample container and heated to about 10°C above the apparent melting temperature (i.e., the apparent T m ; identified from the initial screen with a continuous running water bath attached to a thermocouple). The viscosity, measured in cP (centiPoise), was recorded after one (1) minute. Table 4 and FIG. 1 show the viscosity of betaine/urea compositions at different molar ratios of mixture components at 95°C. TABLE 2
- the solvent component mixtures contemplated in the present disclosure need to (A) melt at a temperature between 40°C to about 100°C; and (B) quickly solidify at a temperature between about 20°C to 40°C, thereby quickly forming a robust protein (encapsulated) solid mixture.
- samples of solvent component mixtures were prepared as follows: water at a specific weight percent (wt %) was added to a container, followed by the addition of thirty (30) grams of the solvent mixture components in the specified molar ratio. The solvent components and water were then mixed at 10 ° C above the predicted melting temperature on a hot plate.
- subtilisin protease preparation was subsequently poured onto a sheet of aluminum foil and left at room temperature (i.e., 21°C in this particular case) to solidify.
- the solvent components tested in the present example were: (1) anhydrous betaine (i.e., ⁇ , ⁇ , ⁇ -trimethylglycine), (2) urea, (3) lactose and (4) water. More particularly, the following solvent component mixtures were formulated for encapsulating and stabilizing the solid enzyme (Properase®): (A) anhydrous betaine/urea (1 : 1 mole ratio) and 5% (weight) water at 85°C, and (B) urea/lactose (6: 1 mole ratio) and 10% (weight) water at 80°C (e.g., see Table 5).
- Etrase® anhydrous betaine/urea (1 : 1 mole ratio) and 5% (weight) water at 85°C
- B urea/lactose (6: 1 mole ratio) and 10% (weight) water at 80°C (e.g., see Table 5).
- FPDSM formulated (protease) enzyme i. e., Properase ® ; formulated as described above in Example 2
- the solidified enzyme cast from encapsulation was transferred to a tared 250 mL Nalgene bottle and weighed.
- Tris buffer pH 8.6
- the resulting dissolved liquid (subtilisin protease) preparation was tested for proteolytic activity against the substrate N-succinyl-L-Ala- L-Ala-L-Pro-L-Phe-/J>-nitroanilide (hereinafter, "Suc-AAPF-pNA"; Sigma, St. Louis, MO, Product No. S- 7388), wherein Suc-AAPF-pNA was used as to make standard curve.
- the Suc-AAPF-pNA control and UFC purified protease (Properase ® ) were used as standards, wherein Suc-AAPF-pNA was used as substrate (as generally described in Example 4 of U.S. Patent Publication No. US2015/0147768).
- Suc-AAPF-pNA assay was generally performed as follows: In order to determine protease activity, the hydrolysis of N-succinyl-L-alanyl-L-alanyl-L-prolyl-L-phenyl-p-nitroanilide (suc- AAPF-pNA) was measured.
- the reagent solutions used were: 100 mM Tris/HCl, pH 8.6, containing 0.005% TWEEN ® -80 (Tris dilution buffer); 100 mM Tris buffer, pH 8.6, containing 10 mM CaCl.sub.2 and 0.005% TWEEN ® -80 (Tris/Ca buffer); and 160 mM suc-AAPF-pNA in DMSO (suc-AAPF-pNA stock solution) (Sigma: S-7388).
- suc-AAPF-pNA working solution 1 ml suc-AAPF-pNA stock solution was added to 50 ml Tris/Ca buffer and mixed repeatedly.
- the assay was performed by adding 5 ⁇ of diluted culture supernatant to each well containing 150 ⁇ Tris dilution buffer, immediately followed by the addition of 100 ⁇ of 2 mg/ml suc-AAPF-pNA working solution. The solutions were mixed for 5 seconds, and the absorbance change in kinetic mode (1 1 readings in 2 minutes) was read at 405 nm in an MTP reader, at 25°C The protease activity was expressed as AU absorbance at 405 nm.
- Anhydrous Betaine Urea (1: 1) + 5% weight water; heated to 85°C, enzyme added and hand-mixed for 60 seconds.
- Properase® protease enzyme was added to FPDSM solvent component mixtures at different temperatures (e.g., see, FIG. 3). For example, specific temperatures were chosen wherein a specific solvent component mixture would remain a molten liquid system. Thus, as set forth in FIG. 3, the Properase ® enzymatic activity (as measured by the "Suc-AAPF-pNA assay" described above) was recorded and plotted as a function of temperature. As presented in FIG. 3, there is an evident decrease in protease activity at mixing temperatures generally exceeding 80-85 ° C. EXAMPLE 6
- a protein of interest is formulated in an approximately 420 grams of a solvent component mixture comprising urea/betaine (1 : 1) + water (4.5%) formulation, according to the following protocol.
- a protein of interest was formulated in an approximately 1 OOg solvent component mixture comprising urea/lactose (6: 1) and water (4.4%), according to a similar protocol as described above in Example 6.
- Procedure Set up / Get ready a 95 ° C and an 85 ° C hot water bath.
- proteins e.g., enzymes
- protein degradation e.g., heat, oxidation, UV light degradation, contaminants, and the like
- a protease enzyme e.g., Properase ®
- FPDSM system i.e., comprising urea and lactose
- the solvent component mixtures were prepared using lactose and urea with a bulk congealing method as described in the following exemplary procedure for a 30 g batch, consisting of 90 mol% urea and 10 mol% lactose (i. e., urea/lactose; 9: 1) and approximately 4.5 wt% water and approximately 5.4 wt% (Properase ® ) enzyme.
- the ground materials were subsequently screened using a Retsch Vibratory Sieve Shaker and size- classified.
- the residual protease activity was greater than 88% during the first month (i. e., 28-days) of storage for all urea/lactose solvent composition ratios tested (i. e., 9: 1, 8.5 : 1.5, 3 : 1 and 6:4).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762580581P | 2017-11-02 | 2017-11-02 | |
PCT/US2018/058665 WO2019089898A1 (fr) | 2017-11-02 | 2018-11-01 | Compositions de matrices solides à point de congélation abaissé pour la granulation à l'état fondu d'enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3703661A1 true EP3703661A1 (fr) | 2020-09-09 |
Family
ID=64362697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18804821.9A Pending EP3703661A1 (fr) | 2017-11-02 | 2018-11-01 | Compositions de matrices solides à point de congélation abaissé pour la granulation à l'état fondu d'enzymes |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3703661A1 (fr) |
WO (1) | WO2019089898A1 (fr) |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310675A (en) | 1983-06-24 | 1994-05-10 | Genencor, Inc. | Procaryotic carbonyl hydrolases |
US4760025A (en) | 1984-05-29 | 1988-07-26 | Genencor, Inc. | Modified enzymes and methods for making same |
US5182204A (en) | 1984-05-29 | 1993-01-26 | Genencor International, Inc. | Non-human carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors |
US5763257A (en) | 1984-05-29 | 1998-06-09 | Genencor International, Inc. | Modified subtilisins having amino acid alterations |
JP2599946B2 (ja) | 1986-01-15 | 1997-04-16 | アムジェン,インコーポレイテツド | ズブチリシン類似体 |
US4980288A (en) | 1986-02-12 | 1990-12-25 | Genex Corporation | Subtilisin with increased thermal stability |
US4914031A (en) | 1987-04-10 | 1990-04-03 | Amgen, Inc. | Subtilisin analogs |
DK6488D0 (da) | 1988-01-07 | 1988-01-07 | Novo Industri As | Enzymer |
PT89702B (pt) | 1988-02-11 | 1994-04-29 | Gist Brocades Nv | Processo para a preparacao de novos enzimas proteoliticos e de detergentes que os contem |
DE3909096A1 (de) | 1989-03-20 | 1990-09-27 | Garabed Antranikian | Alpha-amylase |
US5665587A (en) | 1989-06-26 | 1997-09-09 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
DK97190D0 (da) | 1990-04-19 | 1990-04-19 | Novo Nordisk As | Oxidationsstabile detergentenzymer |
US5482849A (en) | 1990-12-21 | 1996-01-09 | Novo Nordisk A/S | Subtilisin mutants |
WO1992019729A1 (fr) | 1991-05-01 | 1992-11-12 | Novo Nordisk A/S | Enzymes stabilisees et compositions detergentes |
AU682863C (en) | 1993-02-11 | 2003-05-08 | Genencor International, Inc. | Oxidatively stable alpha-amylase |
EP0640138B1 (fr) | 1993-02-25 | 2001-12-19 | Kao Corporation | Fragment d'adn contenant un gene, codant pour la pullulanase alcaline |
DE4411223A1 (de) | 1994-03-31 | 1995-10-05 | Solvay Enzymes Gmbh & Co Kg | Verwendung alkalischer Proteasen in gewerblichen Textilwaschverfahren |
CA2305191C (fr) | 1997-10-13 | 2011-09-27 | Novo Nordisk A/S | Mutants d'.alpha.-amylase |
MA24811A1 (fr) | 1997-10-23 | 1999-12-31 | Procter & Gamble | Compositions de lavage contenant des variantes de proteases multisubstituees |
US6562612B2 (en) | 1997-11-19 | 2003-05-13 | Genencor International, Inc. | Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same |
US6287839B1 (en) | 1997-11-19 | 2001-09-11 | Genencor International, Inc. | Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same |
JP4672864B2 (ja) | 1998-02-27 | 2011-04-20 | ノボザイムス アクティーゼルスカブ | マルトース産生アルファアミラーゼ変異体 |
US6835550B1 (en) | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
US6197565B1 (en) | 1998-11-16 | 2001-03-06 | Novo-Nordisk A/S | α-Amylase variants |
US6268328B1 (en) | 1998-12-18 | 2001-07-31 | Genencor International, Inc. | Variant EGIII-like cellulase compositions |
RU2231547C2 (ru) | 1999-03-30 | 2004-06-27 | Новозимс А/С | Варианты альфа-амилазы |
WO2001025411A1 (fr) * | 1999-10-01 | 2001-04-12 | Novozymes A/S | Produit enzymatique seche par atomisation |
FI108728B (fi) | 1999-10-12 | 2002-03-15 | Carbozyme Oy | Menetelmä perheen G/11 ksylanaasien stabiilisuuden parantamiseksi ja optimaalisen pH-alueen muuttamiseksi |
US7718411B1 (en) | 2004-08-05 | 2010-05-18 | Danisco Us Inc. | Trichoderma reesei G/11 xylanases with improved stability |
WO2001051620A2 (fr) | 2000-01-12 | 2001-07-19 | Novozymes A/S | Variantes de pullulanase et procedes servant a preparer ces variantes presentant des proprietes predeterminees |
WO2001066711A1 (fr) | 2000-03-08 | 2001-09-13 | Danisco A/S | Enzyme |
KR100390565B1 (ko) | 2000-06-20 | 2003-07-07 | 주식회사 씨티씨바이오 | 만난아제를 생산하는 신규한 바실러스 속 wl-1 균주 |
WO2003038035A2 (fr) | 2001-10-26 | 2003-05-08 | Genencor International, Inc. | Enzymes phytase produites par trichoderma reesei, acides nucleiques codant les enzymes phytase, vecteurs et cellules hotes incorporant les enzymes phytase, et methodes de production et d'utilisation des enzymes phytase |
DK1438417T3 (da) | 2001-10-26 | 2014-08-04 | Danisco Us Inc | Phytase-enzymer, nukleinsyresekvenser, der koder for fytase-enzymer ogvektorer og værtsceller, der inkorporerer disse |
MXPA04006811A (es) | 2002-01-16 | 2004-10-11 | Genencor Int | Variantes de proteasa substituidas con multiplos. |
DK1546316T3 (da) | 2002-08-12 | 2011-02-14 | Danisco Us Inc | Mutant E. Coli-AppA-fytaseenzymer og naturlige varianter deraf, nukleinsyrer, der koder for sådanne fytaseenzymer, vektorer og værtsceller, som inkorporerer disse og fremgangsmåder til at fremstille og anvende disse |
CA2523328C (fr) | 2003-04-29 | 2012-07-03 | Genencor International, Inc. | Cellulase 029cel de bacille isolee |
EP1618182B1 (fr) | 2003-04-30 | 2013-07-10 | Genencor International, Inc. | NOUVELLE CELLULASE mHKcel ISOLEE A PARTIR D'UN BACILLE |
JP2007525179A (ja) | 2003-04-30 | 2007-09-06 | ジェネンコー・インターナショナル・インク | 新規なバチルスBagCelセルラーゼ |
RU2006131052A (ru) * | 2004-01-30 | 2008-03-10 | БАСФ Акциенгезельшафт (DE) | Стабилизированные композиции фосфатаз |
CA2560588A1 (fr) | 2004-03-25 | 2005-10-06 | Genencor International, Inc. | Proteine de fusion cellulase et construction de fusion cellulase heterologue codant ladite proteine |
DE102004047777B4 (de) | 2004-10-01 | 2018-05-09 | Basf Se | Alpha-Amylase-Varianten mit erhöhter Lösungsmittelstabilität, Verfahren zu deren Herstellung sowie deren Verwendung |
DE102004047776B4 (de) | 2004-10-01 | 2018-05-09 | Basf Se | Gegen Di- und/oder Multimerisierung stabilisierte Alpha-Amylase-Varianten, Verfahren zu deren Herstellung sowie deren Verwendung |
EP1797178B1 (fr) | 2004-10-04 | 2012-09-12 | DuPont Nutrition Biosciences ApS | Citrobacter freudii phytase et homologues |
GB0422052D0 (en) | 2004-10-04 | 2004-11-03 | Dansico As | Enzymes |
GB0423139D0 (en) | 2004-10-18 | 2004-11-17 | Danisco | Enzymes |
WO2006071598A1 (fr) | 2004-12-23 | 2006-07-06 | Genencor International, Inc. | Noyau catalytique de cellulase neutre et procede d'elaboration |
US8034600B2 (en) | 2005-02-18 | 2011-10-11 | Danisco Us Inc. | Polypeptides having alpha-amylase and granular starch hydrolyzing activity |
MY148594A (en) * | 2005-10-12 | 2013-05-15 | Genencor Int | Stable, durable granules with active agents |
EP2059591B1 (fr) | 2006-07-18 | 2012-09-05 | Danisco US Inc. | Composition pour lavage de vaisselle contenant de variantes de protéases |
US7968691B2 (en) | 2006-08-23 | 2011-06-28 | Danisco Us Inc. | Pullulanase variants with increased productivity |
US8383567B2 (en) | 2006-10-06 | 2013-02-26 | Danisco Us Inc. | Cellulase-free enzyme compositions and host cells for producing the same |
AU2008209720C1 (en) | 2007-01-30 | 2016-06-16 | Novozymes A/S | Polypeptides having phytase activty and polynucleotides encoding same |
ES2550477T3 (es) | 2007-02-07 | 2015-11-10 | Danisco Us Inc. | Hidrólisis de almidón utilizando fitasa con una alfa amilasa |
KR20100014954A (ko) | 2007-03-09 | 2010-02-11 | 다니스코 유에스 인크. | 호알칼리성 바실러스 종 α-아밀라아제 변이체, α-아밀라아제 변이체를 함유하는 조성물 및 사용 방법 |
KR20100014500A (ko) | 2007-03-23 | 2010-02-10 | 다니스코 유에스 인크. | 성숙 아밀라아제 단백질에 n-말단 첨가에 의한 아밀라아제 생성 향상 |
US8546121B2 (en) | 2007-05-30 | 2013-10-01 | Danisco Us Inc. | Variants of an alpha-amylase with improved production levels in fermentation processes |
KR20100024395A (ko) | 2007-05-30 | 2010-03-05 | 다니스코 유에스 인크. | 바실러스 리케니포르미스 알파-아밀라아제의 개선된 변이체 |
US20100323426A1 (en) | 2007-06-08 | 2010-12-23 | Bower Benjamin S | Heterologous and Homologous Cellulase Expression System |
WO2009035537A1 (fr) | 2007-09-07 | 2009-03-19 | Danisco Us Inc., Genencor Division | Compositions de cellulase entière fongique filamenteuse enrichies en béta-glucosidase et procédés d'utilisation |
US8247198B2 (en) | 2007-09-21 | 2012-08-21 | Friedrich Srienc | Enzymatic processing in deep eutectic solvents |
MX2010005461A (es) | 2007-11-20 | 2010-06-02 | Danisco Us Inc | Variantes de glucoamilasa con propiedades alteradas. |
HUE052318T2 (hu) | 2008-04-18 | 2021-04-28 | Danisco Us Inc | Bittiauxella sp. fitáz változatok |
US8084240B2 (en) | 2008-06-06 | 2011-12-27 | Danisco Us Inc. | Geobacillus stearothermophilus α-amylase (AmyS) variants with improved properties |
EP2626422A1 (fr) | 2008-06-06 | 2013-08-14 | Danisco US Inc. | Compositions et procédés comprenant des variants de cellulase avec une affinité réduite pour les matières non cellulosiques |
US9090887B2 (en) | 2008-06-06 | 2015-07-28 | Danisco Us Inc. | Variant alpha-amylases from Bacillus subtilis and methods of use, thereof |
CA2742992A1 (fr) | 2008-11-11 | 2010-05-20 | Danisco Us Inc. | Compositions et methodes comportant une variante de subtilisine |
US20100192985A1 (en) | 2008-11-11 | 2010-08-05 | Wolfgang Aehle | Compositions and methods comprising serine protease variants |
CN102300985A (zh) | 2008-12-23 | 2011-12-28 | 丹尼斯科公司 | 具有木聚糖酶活性的多肽 |
GB0922467D0 (en) | 2009-04-24 | 2010-02-03 | Danisco | Feed supplement |
BRPI1012787A8 (pt) | 2009-05-19 | 2019-11-12 | Danisco | polipeptídeos de amilase |
JP2012528598A (ja) | 2009-06-03 | 2012-11-15 | ダニスコ・ユーエス・インク | 改善された発現、活性、及び安定性を有するセルラーゼ変異体、並びにこれらの使用方法 |
EP3599279A1 (fr) | 2009-12-09 | 2020-01-29 | Danisco US Inc. | Compositions et procédés comprenant des variantes de protéase |
NL2004835C2 (en) | 2010-06-07 | 2011-12-08 | Univ Leiden | Process for extracting materials from biological material. |
US20140135252A1 (en) | 2011-04-29 | 2014-05-15 | Danisco Us Inc. | Detergent compositions containing geobacillus tepidamans mannanase and methods of use thereof |
BR112013026675A2 (pt) | 2011-04-29 | 2016-11-29 | Danisco Us Inc | composições detergentes contendo mananase de bacillus sp., e métodos de uso das mesmas |
CN103814129A (zh) | 2011-09-14 | 2014-05-21 | 杜邦营养生物科学有限公司 | 包含具有内切–1,4–β–木聚糖酶活性的酶和具有内切–1,3(4)–β葡聚糖酶活性的酶的组合物 |
WO2013127069A1 (fr) | 2012-02-29 | 2013-09-06 | Danisco Us Inc. | Xylanase thermostable dérivée de thermobifida fusca et ses méthodes d'utilisation |
EP2874506B1 (fr) * | 2012-07-18 | 2019-04-10 | Danisco US Inc. | Méthode pour la fabrication des granulés d'enzymes |
EP2898053B1 (fr) | 2012-09-20 | 2021-08-25 | Danisco US Inc. | Plaques de microtitration pour une libération contrôlée d'éléments de culture vers des cultures cellulaires |
BR112015012904A2 (pt) | 2012-12-07 | 2017-09-12 | Danisco Us Inc | composições e métodos de uso |
WO2014099525A1 (fr) | 2012-12-21 | 2014-06-26 | Danisco Us Inc. | Amylase de paenibacillus curdlanolyticus, et ses procédés d'utilisation |
GB201303666D0 (en) | 2013-03-01 | 2013-04-17 | Goldsborough Andrew S | Sample fixation and stabilisation |
EP3978604A1 (fr) | 2013-03-11 | 2022-04-06 | Danisco US Inc. | Variantes combinatoires d'alpha-amylase |
GB201308843D0 (en) * | 2013-03-14 | 2013-07-03 | Verenium Corp | Phytase formulation |
GB201401680D0 (en) | 2014-01-31 | 2014-03-19 | Dupont Nutrition Biosci Aps | Compositions and methods comprising a xylanase enzyme variant |
WO2016149636A1 (fr) * | 2015-03-19 | 2016-09-22 | Danisco Us Inc | Granulés stables à faible activité d'eau interne |
-
2018
- 2018-11-01 EP EP18804821.9A patent/EP3703661A1/fr active Pending
- 2018-11-01 WO PCT/US2018/058665 patent/WO2019089898A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019089898A1 (fr) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3180429B1 (fr) | Détergents et compositions avec des particules de polymère enzymatique | |
EP2732018B1 (fr) | Granules d'enzyme stables au stockage | |
JP2020158773A (ja) | 洗剤酵素のマイクロカプセル化 | |
EP2840134B1 (fr) | Granules enzymatiques | |
EP1224273B1 (fr) | Granule d'enzyme | |
EP3122859B1 (fr) | Micro-encapsulation faisant intervenir de petites amines | |
US20200181542A1 (en) | Enzyme Slurry Composition | |
US9222060B2 (en) | Triggered release | |
JP2005531308A (ja) | 顆粒の安定化 | |
EP2408909A1 (fr) | Mélanges améliorés contenant des protéases | |
JP2004508040A (ja) | 潤滑化粒体 | |
EP3703661A1 (fr) | Compositions de matrices solides à point de congélation abaissé pour la granulation à l'état fondu d'enzymes | |
EP3765185B1 (fr) | Microencapsulation utilisant des oligomères de sucre aminé | |
Simi et al. | Encapsulation of crosslinked subtilisin microcrystals in hydrogel beads for controlled release applications | |
US11753605B2 (en) | Multi-core granules | |
EP4410941A1 (fr) | Compositions détergentes contenant des enzymes | |
EP4389865A1 (fr) | Protéase recombinante pour le détachement cellulaire | |
EP3697880B1 (fr) | Granulés de poudrage faible | |
Easa et al. | Optimizing the preparation of cross-linked enzyme aggregates (CLEA)-amylase from supermeal worm (Zophobas Morio) | |
EP4206309A1 (fr) | Particules de protéines à blancheur améliorée | |
JP2003289862A (ja) | タンパク質組成物およびタンパク質の保存方法、搬送方法 | |
WO2019125683A1 (fr) | Granulés thermofusibles contenant des enzymes, comprenant un déshydratant thermotolérant | |
US20230193162A1 (en) | Low dusting granules | |
WO2015057619A1 (fr) | Granulé d'argile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200429 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240227 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DANISCO US INC. |